Feb 12 (Reuters) - Urogen Pharma UR8.F:
DATA FROM A LONG-TERM FOLLOW-UP STUDY TO THE OLYMPUS TRIAL THAT SHOWS A MEDIAN DURATION OF RESPONSE OF NEARLY FOUR YEARS IN PATIENTS ACHIEVING COMPLETE RESPONSE WITH JELMYTO PUBLISHED IN THE JOURNAL OF UROLOGY
Source text: ID:nBw3MmwsWa
Further company coverage: UR8.F